Latest Abarceo Pharma News & Updates

See the latest news and media coverage for Abarceo. We track all announcements, press releases, and industry mentions in real time, all in one place.

Abarceo Pharma (Abarceo)

Preclinical biotechnology company developing mitochondrial disease therapeutics

Last updated October 19

Latest news about Abarceo Pharma (Abarceo)

In short: Abarceo presented its diabetes and mitochondrial repair programs at multiple investor and scientific conferences.

October 19 Abarceo

The company will showcase its new approach for treating Type 1 and 2 Diabetes on October 19 in Stockholm to investors.

September 29 Abarceo

Science Director Ruchi Jain and founder Claes Wollheim will present findings on Type 1 Diabetes at the 62nd Annual Meeting.

May 23, 2025 Abarceo

Groundbreaking data on VDAC1 inhibitors is revealed at the 5th Swedish Diabetes Summit via poster by Ruchi Jain and Claes Wollheim.

March 1, 2021 Abarceo

The company raises a total of 21.5 million kronor to develop drug candidates against type 2 diabetes.

September 24 BioStock

CEO Adam Bruce presents Abarceo Pharma at Investing in Life Science 2026.

Never miss news about Abarceo

Track Abarceo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Browse news for competitors to Abarceo and other trending companies.